Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 601–700 of 1,733
Sexual health and function in liver disease
Ferrarese, A., de León, I. H.-D., Tapper, E. B., & Burra, P. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000691 · Cited by 13
“[ 39 ] Research on the effects of testosterone treatment for ED and low libido has yielded mixed results.”
Huang, Y., Liu, W. X., Chen, S., Liu, Y., Chen, B., Deng, C., & Lu, M. (2018) · International Journal of Impotence Research · doi:10.1038/s41443-018-0090-y · Cited by 12
Yan, Z., & Lei, T. (2022) · Brain Sciences · doi:10.3390/brainsci12060796 · Cited by 15
“common diseases, this may lead to the under- or over-diagnosis of hypogonadism [11,12].”
BackgroundMassa, G., Zambelli, L., Zecca, E., Shkodra, M., Tinè, G., & Caraceni, A. T. (2024) · The Oncologist · doi:10.1093/oncolo/oyae024 · Cited by 13
Shah, R. S., Rambhatla, A., Atmoko, W., Martinez, M. P., Ziouziou, I., Kothari, P., Tadros, N. N., Phuoc, N. H. V., Kavoussi, P. K., Harraz, . M., et al. (2024) · The World Journal of Men s Health · doi:10.5534/wjmh.230333 · Cited by 13
“…to the changes in serum sex-hormone binding globulin (SHBG) levels which may be altered due to metabolic syndrome, hypo/hyperthyroidism, pituitary disease, chronic liver disease, prostate cancer, nephrotic syndrome, estrogen use, as well as drugs such as some anticonvulsants and steroids [38,39].”
Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy
Krishnamurthy, N., Slack, D. J., Kyweluk, M. A., Cullen, O., Kirkley, J., & Safer, J. D. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad651 · Cited by 13
Reddy, K., & Yadav, S. (2021) · Journal of Postgraduate Medicine · doi:10.4103/jpgm.jpgm_887_20 · Cited by 13
“[16] Indian subjects have a higher prevalence of MS and its components at an early age.”
Wh, K., Sithik, M. N. B. M., Khoo, J. K., Ooi, Y., Lim, Q., & Lim, L. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13903 · Cited by 12
Fertility Considerations in Hypogonadal Men
Papanikolaou, N., Luo, R., & Jayasena, C. N. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.009 · Cited by 11
Sun, G., Xue, J., Li, L., Li, X., Cui, Y., Qiao, B., Wei, D., & Li, H. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11235 · Cited by 13
“The actual concentrations, which were measured following addition of pure testosterone, were close to female and male patient levels (1,24).”
BackgroundLongitudinal Changes in Sex Hormone–Binding Globulin in Men With HIV
Pena Dias, J., Haberlen, S. A., Dobs, A. S., Lake, J. E., Palella, F. J., Kingsley, L. A., Price, J. C., Basaria, S., Varadhan, R., Margolick, J. B., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002723 · Cited by 11
Li, H., Gu, Y., Shang, X., Zhou, Y., Zhang, H., Zuo, L., Mei, G., Xia, W., Guan, H.-T., Xiang, W., et al. (2020) · Aging · doi:10.18632/aging.202227 · Cited by 12
“LOH belongs to the organic and primary hypogonadism resulted from the failure of testis to produce physiological concentrations of testosterone [11, 12].”
BackgroundD’Amico, E., Zanghì, A., Burgio, G., Chisari, C. G., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Patti, F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00756 · Cited by 11
How to manage low testosterone level in men: a guide for primary care
Al‐Sharefi, A., Wilkes, S., Jayasena, C. N., & Quinton, R. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x710729 · Cited by 12
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces
Deligiorgi, M. V., Liapi, C. A., & Trafalis, D. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1869211 · Cited by 13
Androgen deficiency is associated with a better prognosis in glioblastoma
Fariña-Jerónimo, H., Martín-Ramírez, R., González-Fernández, R., Medina, L., de Vera, A., Martín-Vasallo, P., & Bello, J. P. (2024) · European journal of medical research · doi:10.1186/s40001-024-01648-3 · Cited by 12
“Considering the definition of AD [25, 26], most of the study patients showed abnormalities in their circulating androgen levels, according to their sex and/or age.”
BackgroundMethodMartínez-Escribano, A., Maroto-García, J., Ruiz-Galdón, M., Barrios-Rodríguez, R., Álvarez-Millán, J. J., Cabezas-Sánchez, P., Plaza-Andrades, I., Molina-Vega, M., Tinahones, F. J., Queipo-Ortuño, M. I., et al. (2020) · Biomolecules · doi:10.3390/biom10121697 · Cited by 11
“The rationale for this was that no differentiated cut-offs values for both techniques are available and, in addition, most clinical guidelines use testosterone cut-off values derived from LC-MS/MS assays [8].”
BackgroundMethodInfluentialDunn, M., Dawe, J., Eu, B., Lee, K., Piatkowski, T. M., & Stoove, M. A. (2024) · Drug and Alcohol Review · doi:10.1111/dar.13899 · Cited by 11
Xu, Z., Chen, X., Zhou, H., Ren, C., Wang, Q., Pan, Y., Liu, L., & Liu, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1335146 · Cited by 14
Plasma androgens and the presence and course of depression in a large cohort of men
de Wit, A. E., Giltay, E. J., de Boer, M. K., Nolen, W. A., Bosker, F. J., Penninx, B. W. J. H., & Schoevers, R. A. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105278 · Cited by 12
“However, such a relationship may also be the indirect result of shared symptoms of hypogonadism and major depressive disorder (MDD), such as sexual dysfunction, apathy and fatigue (Bhasin et al., 2018; Corona et al., 2020; Wu et al., 2010), that may additionally also have an effect on mood.”
Integrity of hypothalamic–pituitary‐testicular axis in exceptional longevity
Aleksić, S., Desai, D., Ye, K. Q., Duran, S., Gao, T., Crandall, J. P., Atzmon, G., Barzilai, N., & Milman, S. (2022) · Aging Cell · doi:10.1111/acel.13656 · Cited by 9
“In the results that follow (Figure 1), low TT level was defined as Centers for Disease Control (CDC)- adjusted TT level (Travison et al., 2017; Appendix S1) below the 2.5th percentile for CDC- harmonized levels for young men (264 ng/ dl) (Bhasin et al., 2018).”
MethodZheng, Z., Pan, J., Liu, M., Chen, Z., Zhang, L., Gao, J., Gao, P., & Zhang, X. (2024) · The Aging Male · doi:10.1080/13685538.2024.2346312 · Cited by 13
“Previous studies have shown that men with TD due to androgen deprivation therapy or hypogonadism often have a concomitant decrease in hemoglobin concentration, while TRT can improve hemoglobin concentration [21,22].”
Chu, L., Zheng, S., Gu, X., Wu, Y., Yang, J., & Deng, H. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0267 · Cited by 10
“157 Hypogonad-ism is associated with increasing age, prolonged HIV infection, and decreased CD4 + T cell counts when hypogonadism occurs.”
Liu, C., Huang, S., Lee, Y., Lee, C., Huang, T.-Y., Geng, J., Chang, C.-W., Lin, C.-Y., Juan, Y., Wu, W., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1252774 · Cited by 9
“It can enhance muscle mass, improve bone density, reduce body fat, and lower total cholesterol levels physiologically (35, 36).”
BackgroundManagement of male obesity-related secondary hypogonadism: A clinical update
Shenoy, M. T., Mondal, S., Fernandez, C. J., & Pappachan, J. M. (2024) · World Journal of Experimental Medicine · doi:10.5493/wjem.v14.i2.93689 · Cited by 14
Oral testosterone therapy: past, present, and future
Miller, J. A., Nguyen, T. T., Loeb, C. A., Khera, M., & Yafi, F. A. (2023) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qead003 · Cited by 14
What anabolic–androgenic steroids reveal about the limits of current harm reduction models
Piatkowski, T. M., Nagata, J. M., & Nielsen, S. (2026) · Addiction · doi:10.1111/add.70395 · Cited by 11
The effects of age and obesity on postprandial dynamics of serum testosterone levels in men
de Velde, F. V., Reyns, T., Toye, K. R. C., Fiers, T., Kaufman, J., T'Sjoen, G. G., & Lapauw, B. (2019) · Clinical Endocrinology · doi:10.1111/cen.14141 · Cited by 11
Cai, M., Cui, R., Yang, P., Gao, J., Cheng, X., Sheng, C., Li, H., Sheng, H., Qu, S., & Zhang, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.675525 · Cited by 11
“Hypogonadism was defined as calculated free testosterone (cFT) less than 220 pmol/L along with the presence of symptoms (positive ADAM score) (16, 17).”
BackgroundSimultaneous quantification of total and free testosterone in human serum by LC–MS/MS
Huang, R., Hong, Y., Wu, Y., Li, W., & Liu, W. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04963-6 · Cited by 10
Kazmerski, T. M., Stransky, O. M., Lavage, D. R., Hughan, K. S., Jain, R., Ladores, S., Stalvey, M. S., Tangpricha, V., Taylor‐Cousar, J. L., West, N. E., et al. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.10.023 · Cited by 11
JENKINS, C., Rittel, A. G., Sturdivant, R. X., Wan, J., CLERC, P. G., Manning, E., Jenkins, L. M., Wardian, J., & Graybill, S. D. (2021) · Andrology · doi:10.1111/andr.12990 · Cited by 15
JAK2 Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management
Gangat, N., Szuber, N., & Tefferi, A. (2025) · American Journal of Hematology · doi:10.1002/ajh.70118 · Cited by 15
“Current guidelines generally advise against androgen replacement when Hct is > 50%, and in patients with Hct > 54%, therapeutic phlebotomy may be implemented, testosterone withheld until Hct is at an acceptable level 50%, and therapy resumed at a reduced dose [156, 157].”
Narinx, N., Marriott, R. J., Murray, K., Adams, R., Ballantyne, C. M., Bauer, D. C., Bhasin, S., Biggs, M. L., Cawthon, P. M., Couper, D. J., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae133 · Cited by 10
“13,14 However, there is debate over how best to confirm the diagnosis with biochemical testing.”
Self-citationFacondo, P., Lodovico, E. D., Pezzaioli, L. C., Cappelli, C., Ferlin, A., & Delbarba, A. (2022) · The Aging Male · doi:10.1080/13685538.2022.2046727 · Cited by 14
Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events
Kharaba, Z. J., Buabeid, M. A., Ibrahim, N. A., Jirjees, F., Al-Obaidi, H. J., Kaddaha, A., Khajehkarimoddini, L., & Alfoteih, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110423 · Cited by 14
Testosterone Therapy in Older Men: Present and Future Considerations
Yeap, B. B., Tran, C., Douglass, C. M., & McNeil, J. J. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01209-1 · Cited by 11
“Whilst T4DM and TRAVERSE both offer reassurance as to prostate safety, men with appreciable background risk should be screened for the presence of prostate cancer prior to starting therapy [3, 4].”
InfluentialIs a fasting testosterone level really necessary for the determination of androgen status in men?
Livingston, M. A., Hackett, G. I., Ramachandran, S., & Heald, A. H. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.06.026 · Cited by 10
Newer formulations of oral testosterone undecanoate: development and liver side effects
Goldstein, I., Chidambaram, N., Dobs, A. S., King, S. M., Miner, M. M., Ramasamy, R., Yafi, F. A., & Khera, M. (2024) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeae062 · Cited by 11
“2,4,15,26 Because native testosterone had poor oral absorption and methyltestosterone was associated with liver toxicity, other routes were explored that are now approved for use, including buccal, intranasal, transdermal, subcutaneous, and intramuscular.”
BackgroundZhang, S., Yang, B., Shen, X., Chen, H., Wang, F., Tan, Z., Ou, W., Yang, C., Liu, C., Peng, H. Y., et al. (2024) · Cell Proliferation · doi:10.1111/cpr.13680 · Cited by 14
“8 As a consequence, TRT further hinders spermatogenesis and cannot address the issue of male infertility.”
BackgroundPrimary and Secondary Hypogonadism in Male Persons with Diabetes Mellitus
Martins, J. M., Jorge, M. D. P., Maia, C. M., Roque, J., Lemos, C., Nunes, D., Reis, D., & Mota, C. (2021) · International Journal of Endocrinology · doi:10.1155/2021/8799537 · Cited by 12
“Case detection of symptomatic individuals rather than screening for low testosterone levels is proposed [21, 22].”
BackgroundInfluentialFunctional hypogonadism in middle-aged and older men: testosterone treatment or not?
Grossmann, M., & Jones, T. H. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0362 · Cited by 11
Puy, V., Mayeur, A., Levy, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa041 · Cited by 10
Endocrine disorders after heart transplantation: national cohort study
Rakuša, M., Vrtovec, B., Poglajen, G., Janež, A., & Jensterle, M. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0533-6 · Cited by 11
Walravens, J., Sleumer, B., Vos, M. J., Snaterse, G., Narinx, N., Antonio, L., Reyns, T., Fiers, T., Kema, I. P., Kaufman, J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae280 · Cited by 11
The Illusory Case for Treatment of an Invented Disease
Handelsman, D. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.682620 · Cited by 12
“This modern elastic redefinition of “hypogonadism” broadens its boundaries to include any lowering of serum testosterone in one or more blood samples coupled with any of a long list of non-specific clinical features (13).”
BackgroundWang, J., Lan, H., Mao, X., & Chen, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03140-4 · Cited by 10
Safety of Testosterone-Replacement Therapy in Older Men
ORWOLL, E. S. (2023) · New England Journal of Medicine · doi:10.1056/nejme2305946 · Cited by 12
Petersen, A. S., Kristensen, D. M., Westgate, C. S. J., Hansen, T. F., Lund, N. L. T., Barloese, M. C. J., Søborg, M.-L. K., Snoer, A. H., Johannsen, T. H., Frederiksen, H. W., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26906 · Cited by 11
“20 A randomized controlled trial from the same group investigated the effect of a single intramuscular administration of a slow-release GnRH analogue, leuprolide 3.75 mg, as compared to placebo (saline).”
BackgroundInfluentialThrombophilia and hormonal therapy in transgender persons: A literature review and case series
Marianne, K., Vantilborgh, A., Collet, S., & T'Sjoen, G. G. (2022) · International Journal of Transgender Health · doi:10.1080/26895269.2022.2025551 · Cited by 13
Testosterone and Glucose Homeostasis in Adult Males: Current Insights and Future Prospects
Milionis, C., Koukkou, E. G., Venaki, E., & Ilias, Ι. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436184.81 · Cited by 12
Arinno, A., Apaijai, N., Kaewthep, P., Pratchayasakul, W., Jaiwongkam, T., Kerdphoo, S., Chattipakorn, S. C., & Chattipakorn, N. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0673 · Cited by 11
Appiah, L. A., Moravek, M. B., Hoefgen, H. R., Rotz, S. J., Childress, K. J., Samis, J. H., Benoît, J., Rodriguez‐Wallberg, K. A., & Anazodo, A. C. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30551 · Cited by 9
Mathiesen, S., Sørensen, K., Ifversen, M., Hagen, C. P., Petersen, J. H., Juul, A., & Müller, K. (2021) · Endocrine Connections · doi:10.1530/ec-21-0154 · Cited by 10
Puberty Induction in Adolescent Males: Current Practice
Alenazi, M. S., Alqahtani, A. M., Ahmad, M. M., Almalki, E., Almutair, A., & Almalki, M. (2022) · Cureus · doi:10.7759/cureus.23864 · Cited by 14
“Monitoring is highly recommended and has been standardized for testosterone therapy in hypogonadal men in the recent guideline [61], but such clear guidance is lacking for adolescents [46,66] and studies have shown that these adolescents on testosterone therapy undergo insufficient and incomplete biochemical monitorin…”
BackgroundInfluentialCandela, L., Boeri, L., Capogrosso, P., Oreggia, D., Cazzaniga, W., Pozzi, E., Belladelli, F., Baudo, A., Abbate, C., Montorsi, F., et al. (2020) · International Journal of Impotence Research · doi:10.1038/s41443-020-0340-7 · Cited by 9
Risks of Serious Injury with Testosterone Treatment
Yarnell, C. J., Thiruchelvam, D., & Redelmeier, D. A. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.07.037 · Cited by 10
Malin, A. J., Busgang, S. A., Garcia, J. C., Bose, S., & Sanders, A. P. (2021) · Exposure and Health · doi:10.1007/s12403-021-00448-y · Cited by 10
“Elevated serum SHBG is linked with hyperthyroidism, cirrhosis of the liver, and polymorphisms in the SHBG gene (Bhasin et al. 2018; NHANES 2018).”
BackgroundStancampiano, M. R., Meroni, S. L. C., Bucolo, C., & Russo, G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402579 · Cited by 11
“Hormone replacement therapy (HRT), if needed, consists of Testosterone treatment, with formulations and therapeutic schemes recommended in International clinical practice guidelines (66 – 68), that we have summarized in Table 4.”
MethodBraga, M. A. P., Rivera, A., Marinheiro, G., Felix, N. S., Carvalho, P. E. P., Gewehr, D. M., Teixeira, L., Clemente, M. R. C., Reis, P. C. A., de Amorim, L. G. C. R., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00737-w · Cited by 10
“…Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypo-gonadal Men have historically raised concern among both clinicians and patients, especially for men with elevated cardiovascular risk profiles, such as middle-aged and older men [13, 14, 43].”
Liu, D., Zhao, R., Zhao, S., Wang, Z., Liu, R., Wang, F., & Gao, Y. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.123002 · Cited by 9
Therapeutic Phlebotomy for Testosterone-Induced Polycythemia
Buren, N. L. V., Hove, A. J., French, T. A., & Gorlin, J. B. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa019 · Cited by 10
Vasan, S., Pandey, S., Rao, S., Gupte, D., Gangavaram, R. R., Saxena, A. K., KOVIL, R. R., Joshi, P., Goel, R., Mittal, S. K., et al. (2025) · Cureus · doi:10.7759/cureus.77851 · Cited by 26
Berryman, C. E., McClung, H. L., Sepowitz, J. J., Gaffney‐Stomberg, E., Ferrando, A. A., McClung, J. P., & Pasiakos, S. M. (2022) · Physiological Reports · doi:10.14814/phy2.15461 · Cited by 11
“Furthermore, to diagnose hypogonadism, the Endocrine Society Clinical Practice Guideline recommends conducting a medical history and physical exam, measuring fasting morning testosterone concentrations, and then confirming a low testosterone outcome by repeat measurement (Bhasin et al., 2018).”
MethodKing, B., Natale, C., & Hellstrom, W. J. G. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2022.07.009 · Cited by 11
Diagnosis and Evaluation of Hypogonadism
Matsumoto, A. M. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.001 · Cited by 9
Self-citationLafitte, A., Dupuit, M., Chassard, T., Barlier, K., Badier, N., Duclos, M., Toussaint, J., & Antero, J. (2024) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2024-002078 · Cited by 13
Rivero, M., Ory, J., Diaz, P., Thirumavalavan, N., Han, S., Reis, I., & Ramasamy, R. (2023) · Journal of Urology · doi:10.1097/ju.0000000000003487 · Cited by 8
“TESTOSTERONE deficiency (TD) is characterized by low serum testosterone (T) levels associated with clinical symptoms such as fatigue, decreased muscle mass, decreased libido, depressed mood, and sexual dysfunction.(1,2) TD affects at least 5% of men worldwide, with a higher incidence in the elderly, and typically occu…”
BackgroundMethodJathal, I., Wang, Y., Binongo, J., Cobb, C., Hunt, W. R., Khan, F. N., & Tangpricha, V. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.07.013 · Cited by 9
de Silva, N. L., Dissanayake, H. A., Arbeláez, M. C. S., Wickramarachchi, R., Ramasamy, R., Dhillo, W. S., Minhas, S., Corona, G., & Jayasena, C. N. (2023) · Andrology · doi:10.1111/andr.13480 · Cited by 12
Male sexual dysfunction: Clinical diagnosis and management strategies for common sexual problems
Nicol, A. V., & Chung, E. (2023) · Australian Journal of General Practice · doi:10.31128/ajgp-09-22-6559 · Cited by 18
Association of hypogonadism symptoms and serum hormones in aging males
Liang, G.-Q., Song, Y., Liu, L., Zhou, K., Tian, J. H., Li, J., Shi, H., Zhu, Q., Wang, J., Zheng, J.-B., et al. (2021) · Andrologia · doi:10.1111/and.14013 · Cited by 10
Semen quality in hypogonadal acromegalic patients
Andreassen, M., Juul, A., Feldt‐Rasmussen, U., & Jørgensen, N. (2019) · Pituitary · doi:10.1007/s11102-019-01018-x · Cited by 11
Metabolic Syndrome, Hepatic Steatosis and Testosterone: A Matter of Sex
Gangitano, E., Scannapieco, F., Lubrano, C., & Gnessi, L. (2024) · Livers · doi:10.3390/livers4040038 · Cited by 11
“In addition, the pro-inflammatory cytokines such as TNF-α and IL-1 may reduce SHBG levels, resulting in increased free testosterone, which stimulates aromatase activity and the conversion of testosterone to estradiol and acts with negative feedback on the HPG axis [58].”
Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism
Miner, M. M., Wang, C., Kaminetsky, J. C., Khera, M., Goldstein, I., Carson, C. C., Chidambaram, N., King, S. M., & Dobs, A. S. (2024) · Andrology · doi:10.1111/andr.13747 · Cited by 9
Common Pitfalls in the Interpretation of Endocrine Tests
Álvarez-Payares, J. C., Bello-Simanca, J. D., Peña-Arrieta, E. D. J. D. L., Agamez-Gomez, J. E., García-Rueda, J. E., Rodriguez-Arrieta, A., & Arrieta, L. A. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.727628 · Cited by 16
Lisco, G., Triggiani, V., Bartolomeo, N., Ramunni, M. I., Pelusi, C., Pergola, G. D., Guastamacchia, E., Jirillo, E., & Giagulli, V. A. (2023) · Basic and Clinical Andrology · doi:10.1186/s12610-022-00182-8 · Cited by 10
“Conversely, organic forms of male hypogonadism include every condition in which an exogen injury or endogen cause affects the hypothalamic-pituitary-testicular axis irreversibly [17].”
BackgroundResultInfluentialErectile Dysfunction in Diabetic Patients: From Etiology to Management
Cannarella, R., Barbagallo, F., Condorelli, R. A., Gusmano, C., Crafa, A., Vignera, S. L., & Calogero, A. E. (2021) · Diabetology · doi:10.3390/diabetology2030014 · Cited by 12
Gender-affirming hormone treatment: friend or foe? Long-term follow-up of 755 transgender people
Santi, D., Spaggiari, G., Marinelli, L., Cacciani, M., Scipio, S., Bichiri, A., Profeta, A., Granata, A. R. M., Simoni, M., Lanfranco, F., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02220-2 · Cited by 13
Investigating the basis of sexual dysfunction during late-onset hypogonadism
Tharakan, T., Miah, S., Jayasena, C. N., & Minhas, S. (2019) · F1000Research · doi:10.12688/f1000research.16561.1 · Cited by 10
Correction of Androgen Deficiency in Men with Type 2 Diabetes
Kobyliak, N. M., Pankiv, V. І., Yuzvenko, Т. Y., et al. (2021) · Reviews on Recent Clinical Trials · doi:10.2174/1574887116666211202155304 · Cited by 9
Jiang, R., & Wang, Y. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-09973-7 · Cited by 12
“Normal testosterone levels for females are 15–70 ng/dL, while the normal range for males is 300–1000 ng/dL. Clinically, symptomatic males with total testosterone lower than 300 ng/dL should be treated with testosterone therapy [27, 28].”
Aghazadeh, Y., Venugopal, S., Martinez-Arguelles, D. B., Boisvert, A., Blonder, J., & Papadopoulos, V. (2019) · Endocrinology · doi:10.1210/endocr/bqz036 · Cited by 9
Asia–Pacific consensus for the management of osteoporosis in men
Huang, C., Ho, C.-J., Lin, S.-Y., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07559-1 · Cited by 9
Is it Time to Test the Effect of Weight Loss on Testosterone?
Singh, A., & Dobs, A. S. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.289355 · Cited by 9
Lolck, K. V., Alcázar, J., Kamper, R. S., Haddock, B., Hovind, P. H., Dela, F., & Suetta, C. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03107-3 · Cited by 11
Functional Hypogonadism and Testosterone Deficiency in Aging Males With and Without HIV-infection
Postel, N., Wolf, E., Balogh, A., Obermeier, M., Degen, O., Mayr, C., Baumgarten, A., Pauli, R., Mueck, B., Jaeger, H., et al. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1210-2482 · Cited by 9
Spurious Serum Hormone Immunoassay Results: Causes, Recognition, Management
Braunstein, G. D. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.141 · Cited by 9
“In these instances, measurement of the free or unbound hormone concentrations or calculation of the approximate free hormone concentration from measurement of the total hormone level and the binding protein concentration(s) will provide the correct information concerning the circulating hormone concentration.(4,5) An…”
BackgroundVaranoske, A. N., Harris, M. N., Hebert, C., Howard, E. E., Johannsen, N. M., Heymsfield, S. B., Greenway, F. L., Margolis, L. M., Lieberman, H. R., Beyl, R. A., et al. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00190.2022 · Cited by 10
de Oliveira, I. C. V., Galvão-Moreira, L. V., Vilela, J. L., Duarte-Silva, M., da Silva, L. D. A., Abreu‐Pereira, C. A., Pereira, D. M. S., Pinheiro, A. J. M. C. R., Neto, L. G. L., Fernandes, E. S., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109669 · Cited by 10
Reid, K. F., Storer, T. W., Pencina, K. M., Valderrábano, R. J., Latham, N. K., Wilson, L. A., Ghattas, C., Dixon, R., Nunes, A., Bajdek, N., et al. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05441-3 · Cited by 9
“The testosterone undecanoate dose for men (first dose of 750-mg on the day of randomization, second 750-mg dose during week 4, and the third 750-mg dose during week 14) is based on the approved regimen and Endocrine Society guidelines [40, 43].”
BackgroundMethodSelf-citationGagliano‐Jucá, T., Pencina, K. M., Shang, Y. V., Travison, T. G., Lincoff, A. M., Nissen, S. E., Artz, A. S., Li, X., Chan, A., Patel, R., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.04.004 · Cited by 11
Self-citationTestosterone and aging male, a perspective from a developing country
Hoai, B. N., Long, H., Thắng, N. C., Pham, Q. M., & Jannini, E. A. (2023) · The Aging Male · doi:10.1080/13685538.2023.2223712 · Cited by 15
“Indeed, unexplained anemia has been noted as a non-specific symptom suggesting TD for which the treatment needs to be considered according to the guidelines of the Endocrine Society in 2018 [114].”
BackgroundBone biochemical markers in acromegaly: An association with disease activity and gonadal status
Pişkinpaşa, M. E. (2020) · Northern Clinics of Istanbul · doi:10.14744/nci.2020.35467 · Cited by 9
Pichilingue, A. P., Greene, D. N., & Krasowski, M. D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22819 · Cited by 10
“This has led some authorities, including the Endocrine Society in their clinical practice guideline for hypogonadal men, to recommend that the preferred specimen for serum testosterone measurement is a fasting morning specimen [11].”
BackgroundInfluentialJayasena, C. N., de Silva, N. L., O’Reilly, M., MacKenzie, F., Marrington, R., Jones, H. T., Livingston, M. A., Downie, P., Hackett, G. I., Ramachandran, S., et al. (2023) · Clinical Endocrinology · doi:10.1111/cen.14929 · Cited by 11
“1,19 22 Even then, there is little evidence for the benefit of testosterone replacement therapy in men with serum testosterone >12 nmol/L.”
Self-citationDiaz, P., Reddy, R. S., Blachman-Braun, R., Zucker, I. J., Dullea, A. D., González, D., Kresch, E., & Ramasamy, R. (2022) · The World Journal of Men s Health · doi:10.5534/wjmh.210261 · Cited by 8
“Hypogonadism in men presents as a clinical syndrome of low serum testosterone and decreased spermatogenesis combined with symptoms of erectile dysfunction, suppressed mood, and decreased libido [1,2].”
BackgroundKolliari-Turner, A., Lima, G. H. O., Wang, G., Malinsky, F. R., Karanikolou, A., Eichhorn, G., Tanisawa, K., Betancurt, J. A. O., Hamilton, B., Kumi, P. Y. O., et al. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01512-z · Cited by 9
“, > 100 mg/week) [24, 25] and thereby confound the data collected post initial AAS usage.”
BackgroundGrossmann, M., Fui, M. N. T., Hoermann, R., & Wittert, G. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_96_19 · Cited by 10
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.